What Are the Early Signs of Tardive Dyskinesia from Reglan?

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

Legacy of Informed Medical Decision-Making

If you or a loved one has been taking Reglan and notice involuntary movements like lip smacking or tongue thrusting, it could be tardive dyskinesia. This condition can develop even after the medication is stopped. Building on decades of pharmacovigilance research, this page outlines the key symptoms to watch and when to seek medical evaluation.

Bridge to Reglan and Tardive Dyskinesia

Specifically, the medication Reglan (metoclopramide) has been associated with a serious movement disorder known as tardive dyskinesia, particularly with prolonged use. In Massachusetts, individuals who have been exposed to Reglan in occupational or clinical settings must be aware of the legal timeframes for seeking compensation. The statute of limitations for filing a Reglan tardive dyskinesia claim in Massachusetts is generally three years from the date the injury was discovered or should have been discovered, making timely legal consultation essential for affected workers.

FDA-Approved Labeling and Risk of Tardive Dyskinesia

Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA-approved labeling includes a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the labeling instructs prescribers to use Reglan for the shortest duration of treatment and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, the labeling advises avoiding a total duration of treatment with metoclopramide products, including Reglan tablets, for longer than 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Mechanism and Clinical Presentation of Tardive Dyskinesia

Tardive dyskinesia is characterized by potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling notes that metoclopramide may suppress or partially suppress the signs of TD and may delay the diagnosis of TD because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also warns against concomitant use of other drugs known to cause TD, other extrapyramidal symptoms (EPS), or neuroleptic malignant syndrome (NMS), and advises avoiding use in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If symptoms of TD occur, the labeling instructs immediate discontinuation of Reglan and seeking immediate medical attention (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to tardive dyskinesia involves metoclopramide's dopamine D2 receptor antagonism in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent involuntary movements.

Statute of Limitations for Reglan Claims in Massachusetts

Settlement-related considerations for affected patients in Massachusetts involve the statute of limitations for filing a claim. In Massachusetts, the statute of limitations for personal injury claims, including those related to medication-induced tardive dyskinesia, is generally three years from the date the injury is discovered or reasonably should have been discovered. The timeline between exposure to Reglan and documented harm is critical for determining when the statute of limitations begins. The labeling indicates that TD can develop after varying durations of treatment, and the risk increases with longer use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who develop TD may not immediately recognize the symptoms as related to Reglan, and the labeling's note that metoclopramide can mask TD symptoms further complicates the timeline (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Therefore, the date of diagnosis or the date when a reasonable person would have connected the symptoms to Reglan use is crucial for statute of limitations purposes. For patients considering legal action, documentation of Reglan use, duration of treatment, cumulative dosage, and the onset and diagnosis of TD is essential. The labeling's boxed warning and warnings and precautions section provide evidence that the manufacturer was aware of the risk and included warnings in the prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, the adequacy of these warnings in specific cases may be subject to legal scrutiny, particularly if a patient was prescribed Reglan for longer than the recommended 12-week duration or if monitoring was not performed as advised.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Reglan tardive dyskinesia claims in Massachusetts?

In Massachusetts, the statute of limitations for personal injury claims, including those related to Reglan-induced tardive dyskinesia, is generally three years from the date the injury was discovered or reasonably should have been discovered. This means affected individuals must file a lawsuit within three years of when they knew or should have known that their tardive dyskinesia was caused by Reglan. Because Reglan can mask symptoms, the discovery date may be delayed, so prompt legal consultation is advised.

What evidence is needed to support a Reglan tardive dyskinesia claim?

To support a claim, patients should document their Reglan use, including duration of treatment and cumulative dosage, as well as the onset and diagnosis of tardive dyskinesia. Medical records confirming the diagnosis and linking it to Reglan exposure are crucial. The FDA-approved labeling, which includes a boxed warning about the risk of tardive dyskinesia, can serve as evidence that the manufacturer was aware of the risk. Additionally, any records showing that Reglan was used beyond the recommended 12-week duration or without proper monitoring may strengthen the claim.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Reglan Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.